The stock of Geron Corporation (NASDAQ:GERN) is a huge mover today! About 284,088 shares traded hands. Geron Corporation (NASDAQ:GERN) has declined 16.96% since March 8, 2016 and is downtrending. It has underperformed by 26.27% the S&P500.
The move comes after 8 months positive chart setup for the $397.11M company. It was reported on Oct, 11 by Barchart.com. We have $4.40 PT which if reached, will make NASDAQ:GERN worth $337.54 million more.
Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on November, 3. They expect $-0.06 EPS, down 135.29% or $0.23 from last year’s $0.17 per share. After $-0.05 actual EPS reported by Geron Corporation for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.
Geron Corporation (NASDAQ:GERN) Ratings Coverage
Out of 2 analysts covering Geron (NASDAQ:GERN), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Geron has been the topic of 4 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The rating was maintained by MLV on Monday, August 10 with “Buy”. As per Tuesday, September 13, the company rating was maintained by FBR Capital. The firm has “Overweight” rating given on Monday, December 7 by Piper Jaffray. The firm has “Hold” rating given on Saturday, August 8 by Zacks.
According to Zacks Investment Research, “Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.”
Insitutional Activity: The institutional sentiment decreased to 0.6 in Q2 2016. Its down 0.79, from 1.39 in 2016Q1. The ratio turned negative, as 16 funds sold all Geron Corporation shares owned while 44 reduced positions. 8 funds bought stakes while 28 increased positions. They now own 61.08 million shares or 8.99% less from 67.11 million shares in 2016Q1.
D E Shaw & Co accumulated 0% or 82,408 shares. Opaleye Mgmt has 2.01% invested in the company for 1.30 million shares. Cambridge Invest Rech Advsr owns 21,555 shares or 0% of their US portfolio. Fincl Bank Of America Corporation De last reported 0% of its portfolio in the stock. Millennium Lc accumulated 0% or 453,573 shares. Morgan Stanley has 0% invested in the company for 57,654 shares. Pathstone Family Office Limited Co has 1,000 shares for 0% of their US portfolio. Blackrock Advsrs, a Delaware-based fund reported 72,783 shares. Moreover, Manufacturers Life Insurance The has 0% invested in Geron Corporation (NASDAQ:GERN) for 107,259 shares. Swiss Bank holds 0% of its portfolio in Geron Corporation (NASDAQ:GERN) for 251,500 shares. Bnp Paribas Arbitrage accumulated 0% or 5,872 shares. California State Teachers Retirement Systems accumulated 0% or 316,594 shares. Metropolitan Life Ny holds 0% or 113,715 shares in its portfolio. Moreover, Citigroup has 0% invested in Geron Corporation (NASDAQ:GERN) for 33,738 shares. Moreover, Teacher Retirement System Of Texas has 0% invested in Geron Corporation (NASDAQ:GERN) for 21,964 shares.
More notable recent Geron Corporation (NASDAQ:GERN) news were published by: Fool.com which released: “Here’s Why Geron Corporation Tumbled 16% in September” on October 07, 2016, also Fool.com with their article: “Why Geron Corporation Is Plunging Today” published on September 12, 2016, Streetinsider.com published: “Geron Corp (GERN), Janssen Pharma Enter Exclusive Licensing Agreement” on September 19, 2016. More interesting news about Geron Corporation (NASDAQ:GERN) were released by: Investorplace.com and their article: “Why Geron Corporation (GERN), Polaris Industries Inc. (PII) and VimpelCom Ltd …” published on September 12, 2016 as well as Seekingalpha.com‘s news article titled: “Geron: Promising Signs” with publication date: October 03, 2016.
GERN Company Profile
Geron Corporation (Geron), incorporated on November 28, 1990, is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Firm operates through the segment, which includes discovery and development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that focuses and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.